Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Artes Biotechnology
Artes Biotechnology
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Offering packet solutions for biopharmaceutical processes
Artes Biotechnology, and Minapharm Pharmaceuticals and Chemical Industries have made a business alliance to out-license their respective biopharmaceutical technologies
Research & Development
ARTES and BioSun announce codevelopment for HPV vaccine
ARTES Biotechnology and BioSun Pharmed are tojoin forces to develop and manufacture an HPV (human papilloma virus) vaccine in Iran
Research & Development
Artes Biotechnology and Burnet Institute join forces to develop novel hepatitis C vaccine
The project will combine Burnet's HepSeeVaxDelta3 technology with Artes’ Metavax technology
Research & Development
ARTES and Burnet join forces to develop anti-malaria vaccine
Transmission-blocking vaccines could play a significant role in the eventual eradication of malaria
Manufacturing
ARTES Biotechnology to collaborate with Bio Farma on vaccine development
First agreement for VLP-based vaccine technology transfer signed on 1 July in Bandung
Research & Development
Artes acquires Anavax VLP technology
Will develop processes for specific vaccines
Subscribe now